DA-2811 / Dong-A - LARVOL DELTA

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (clinicaltrials.gov) - P2 | N=288 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control (clinicaltrials.gov) - P4 | N=231 | Completed | Sponsor: Dong-A ST Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2024 ➔ Mar 2025

Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (clinicaltrials.gov) - P4 | N=232 | Recruiting | Sponsor: Dong-A ST Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Dec 2024

Enrollment open • Monotherapy • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects. (PubMed, Drug Des Devel Ther) - "Dapagliflozin formate (DAP-FOR, DA-2811), an ester prodrug of dapagliflozin, was developed to improve the stability and pharmaceutical manufacturing process of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor. The safety profiles were also similar between the two drugs. These results suggest that DAP-FOR can be used as an alternative to DAP-PDH."

Clinical • PK/PD data

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (clinicaltrials.gov) - P4 | N=232 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.

Monotherapy • New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811) (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Dong-A ST Co., Ltd. | Recruiting ➔ Completed

Trial completion